Sacubitril/Valsartan For Heart Failure & Ejection Fraction
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF | JACC: Heart Failure
Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study - eClinicalMedicine
JCM | Free Full-Text | Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease?
Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure | Cardiology Discovery
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure
JCM | Free Full-Text | Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF - ScienceDirect
PDF) Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction | Heart
Frontiers | Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan | NEJM
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction - ScienceDirect
Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan | Circulation: Cardiovascular Quality and Outcomes
Sacubitril/Valsartan For Heart Failure & Ejection Fraction
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF - ScienceDirect
Frontiers | Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril–valsartan | Scientific Reports
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction | Heart
Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan | NEJM
Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study - eClinicalMedicine
Estimating the Lifetime Benefits of Treatments for Heart Failure - ScienceDirect
